{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/medtronic-mdt/",
 "dataUrl": "https://clearank.com/stock/medtronic-mdt/data.json",
 "title": "Medtronic plc (MDT) Stock Forecast & Price Target (2026)",
 "description": "Medtronic (MDT) stock: Healthcare, Medical Devices. $119.9B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Medtronic (MDT)",
 "published": "2026-07-03T09:22:47+00:00",
 "modified": "2026-09-15T22:26:22.333+00:00",
 "generated": "2026-09-16T10:59:50.391Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "MDT",
  "name": "Medtronic",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "Ireland",
  "website": "https://www.medtronic.com"
 },
 "quote": {
  "price": 93.75,
  "previousClose": 93.8,
  "change": -0.05,
  "changePercent": -0.05,
  "open": 93.69,
  "high": 94.7,
  "low": 92.73,
  "volume": 7146652,
  "averageVolume": 8728005,
  "marketCap": 119919177187,
  "fiftyTwoWeekHigh": 106.33,
  "fiftyTwoWeekLow": 73.31,
  "marketOpen": false,
  "asOf": "2026-09-15T22:26:22.000Z"
 },
 "statistics": {
  "pe": 22.40394,
  "eps": 4.06,
  "dividendYield": 0.030706898090276095,
  "beta": 0.574,
  "priceToSales": 3.099206,
  "priceToBook": 2.3179245,
  "revenueTtm": 37541998592,
  "grossMargin": 0.6498564985649856,
  "returnOnEquity": 0.106479995
 },
 "technicals": {
  "rsi": 57.12,
  "macd": 1.23,
  "sma50": 88.1,
  "sma200": 89.44,
  "rsiSignal": "Neutral",
  "trend": "Bearish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 70,
  "consensus": "Buy",
  "fairValue": 106,
  "analystTarget": 106,
  "analystCount": 29,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-15T22:26:22.000Z",
  "priceAtAnalysis": 93.75,
  "volatility": {
   "daily": 1.36,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 91.88,
  "aggressiveEntry": 93.75,
  "stopLoss": 88.94,
  "stopLossPercent": 3.19,
  "targets": [
   96.47,
   101.06,
   105.66
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 71.82,
    "base": 97.22,
    "upside90th": 131.62
   },
   {
    "year": 2028,
    "downside10th": 65.7,
    "base": 100.83,
    "upside90th": 154.74
   },
   {
    "year": 2029,
    "downside10th": 61.88,
    "base": 104.56,
    "upside90th": 176.69
   },
   {
    "year": 2030,
    "downside10th": 59.17,
    "base": 108.44,
    "upside90th": 198.73
   },
   {
    "year": 2031,
    "downside10th": 57.13,
    "base": 112.46,
    "upside90th": 221.37
   },
   {
    "year": 2032,
    "downside10th": 55.54,
    "base": 116.62,
    "upside90th": 244.9
   },
   {
    "year": 2033,
    "downside10th": 54.27,
    "base": 120.94,
    "upside90th": 269.53
   },
   {
    "year": 2034,
    "downside10th": 53.25,
    "base": 125.43,
    "upside90th": 295.42
   },
   {
    "year": 2035,
    "downside10th": 52.43,
    "base": 130.07,
    "upside90th": 322.71
   },
   {
    "year": 2036,
    "downside10th": 51.76,
    "base": 134.89,
    "upside90th": 351.52
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "MDT Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$93.69",
    "Day Range": "$92.73 to $94.70",
    "Prev Close": "$93.80",
    "Volume": "7.15M",
    "52-Week Range": "$73.31 to $106.33",
    "Market Cap": "$119.92B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-30%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "MDT Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, MDT beat estimates 4 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "MDT Analysis",
   "text": [
    "Medtronic (MDT) is currently trading above its 50-day and 200-day moving averages ($88.10 and $89.44), signaling an upward trend. The Relative Strength Index (RSI) is at 57.12, indicating neutral momentum, while the MACD at 1.23 suggests a positive, albeit moderate, trend. The stock's price action over the last quarter has been constructive, consistently trading above key moving averages. Key support levels are near the 50-day SMA around $88.10, while resistance is observed near its recent highs. Volume has been slightly below average recently, with 7.15 million shares traded compared to an average of 8.73 million, suggesting a lack of strong conviction from traders at current levels.",
    "A strong analyst consensus, with 20 out of 29 analysts rating MDT as Buy or Strong Buy, and a median price target of $106.00, suggests confidence in the company's future performance and offers a potential 13.1% upside.",
    "Medtronic (MDT) has a track record of meeting or exceeding earnings expectations, with the latest quarter to September 2026 showing a 4.32% EPS surprise, indicating operational strength.",
    "Medtronic's P/E ratio of 22.40 and P/S ratio of 3.10 are below sector medians, presenting a value opportunity within the Healthcare sector.",
    "Insider transactions indicate net selling pressure, with total sales of $9.6 million compared to purchases of $462.8K, which could signal a cautious outlook from management.",
    "Projected revenue growth for next year is expected to slow to 4.00%, down from approximately 7.00% for the current year, which could impact future valuation multiples.",
    "Medtronic (MDT) is expected to maintain its positive trajectory over the next 6-12 months, driven by its consistent earnings performance and attractive valuation. The median analyst target price of $106.00 suggests a potential upside of 13.1% from the current price of $93.75. The company's revenue is projected to grow by approximately 7.00% for the current year, slightly above the sector average. The positive analyst consensus, with a majority of ratings at Buy or Strong Buy, further supports this outlook. Potential upside catalysts include continued innovation in its medical device segments and favorable healthcare policy developments. Conversely, a significant shift in insider selling sentiment or a slowdown in projected revenue growth could present downside risks."
   ],
   "lists": {
    "ProTips": [
     "Medtronic's (MDT) insider transactions show a moderate sell signal, with total sales significantly outweighing purchases. Investors should monitor future insider activity for any changes in sentiment.",
     "The stock is trading above its 50-day and 200-day moving averages ($88.10 and $89.44), indicating a bullish technical setup. However, recent volume has been below average, suggesting a lack of strong conviction.",
     "Consider position sizing carefully given the moderate insider sell signal, even though the overall analyst consensus remains positive."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Positive Analyst Sentiment and Price Targets",
     "text": "A strong analyst consensus, with 20 out of 29 analysts rating MDT as Buy or Strong Buy, and a median price target of $106.00, suggests confidence in the company's future performance and offers a potential 13.1% upside.",
     "source": "Wall Street Analysts"
    },
    {
     "type": "Bullish",
     "title": "Consistent Earnings Performance",
     "text": "Medtronic (MDT) has a track record of meeting or exceeding earnings expectations, with the latest quarter to September 2026 showing a 4.32% EPS surprise, indicating operational strength.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Attractive Valuation Relative to Sector",
     "text": "Medtronic's P/E ratio of 22.40 and P/S ratio of 3.10 are below sector medians, presenting a value opportunity within the Healthcare sector.",
     "source": "Company Fundamentals"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insider transactions indicate net selling pressure, with total sales of $9.6 million compared to purchases of $462.8K, which could signal a cautious outlook from management.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Moderating Revenue Growth Projections",
     "text": "Projected revenue growth for next year is expected to slow to 4.00%, down from approximately 7.00% for the current year, which could impact future valuation multiples.",
     "source": "Revenue Estimates"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Medtronic (MDT) exhibits a P/E ratio of 22.40, which is below the sector median of 31.9, suggesting a potentially attractive valuation. Its price-to-sales ratio of 3.10 is also below the sector median of 3.7. The company's return on equity stands at 10.65%, and its profit margin is 13.93%, both figures indicating solid profitability. With a debt-to-equity ratio of 0.55, Medtronic maintains a manageable leverage profile. The current valuation appears reasonable given the company's consistent earnings performance and projected revenue growth of approximately 7.00% for the current year, which slightly outpaces the sector average of 8.1%.",
    "Medtronic (MDT) has a history of meeting or exceeding earnings expectations, with the quarter to September 2026 showing an EPS surprise of 4.32%. The company has also demonstrated positive price reactions following earnings reports, such as a 0.46% increase after the quarter to June 2026. Revenue growth is projected to be around 6.00% for the current and next quarters, indicating sustained top-line expansion. This consistent performance suggests operational efficiency and effective market positioning.",
    "A primary risk for Medtronic (MDT) stems from insider transactions, which show a moderate sell signal with total sales of $9.6 million compared to purchases of $462.8K. While the company's valuation is attractive relative to its sector, a significant portion of the selling activity is attributed to officers, which could signal a lack of confidence in near-term price appreciation. Also, while revenue growth is steady, the projected growth rate for next year is expected to moderate to 4.00%, which could impact future valuation multiples."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "119.92B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "22.40"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "4.06"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "3.04%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "106.33"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "73.31"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Neutral SMA Cross Bearish Price vs SMA Bullish MACD Bullish Moving averages show a lagging Death Cross (50-day: $88.10, 200-day: $89.44), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "57.12"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "1.23"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "88.10"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "89.44"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.25",
    "Correlation with Nasdaq 100 (QQQ)": "+0.11",
    "Correlation with Bitcoin (BTC)": "-0.18",
    "Correlation with Gold (XAU)": "+0.07"
   }
  },
  {
   "id": "trade-plans",
   "title": "MDT Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (57.1) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$96.47",
    "TARGET 2": "$101.06",
    "TARGET 3": "$105.66",
    "STOP LOSS": "$88.94"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+4.00%",
    "Average Feb return": "-1.73%",
    "Average Mar return": "-1.93%",
    "Average Apr return": "+1.97%",
    "Average May return": "-0.73%",
    "Average Jun return": "+0.28%",
    "Average Jul return": "+2.76%",
    "Average Aug return": "+2.77%",
    "Average Sep return": "-1.96%",
    "Average Oct return": "-2.74%",
    "Average Nov return": "+1.62%",
    "Average Dec return": "-1.83%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.36%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in MDT in September 2016 would be worth about $10,950 today, compared with about $35,344 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MDT today could grow to about $14,389 by 2036 in the base case, with a bull case near $37,496 and a bear case around $5,522. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "MDT Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $108 for MDT by 2030 in the base case, from $93.75 today (1.2x over 4 years). The downside path ends near $59.17. These are outcomes of a Monte Carlo simulation run on MDT's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using MDT's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "MDT simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$71.82",
        "$97.22",
        "$132"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$65.70",
        "$101",
        "$155"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$61.88",
        "$105",
        "$177"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$59.17",
        "$108",
        "$199"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$57.13",
        "$112",
        "$221"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$55.54",
        "$117",
        "$245"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$54.27",
        "$121",
        "$270"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$53.25",
        "$125",
        "$295"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$52.43",
        "$130",
        "$323"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$51.76",
        "$135",
        "$352"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "SYK Stryker Corp. NYSE $281.50 -0.13%",
     "url": "https://clearank.com/stock/stryker-syk/"
    },
    {
     "text": "ILMN Illumina Inc. NASDAQ $222.36 +6.80%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "BMY Bristol-Myers Squibb Company NYSE $63.73 -0.58%",
     "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.87 -2.62%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    },
    {
     "text": "TEM Tempus AI Inc NASDAQ $68.85 +10.67%",
     "url": "https://clearank.com/stock/tempus-ai-tem/"
    },
    {
     "text": "RGNX Regenxbio Inc. NASDAQ $7.95 -8.57%",
     "url": "https://clearank.com/stock/rgnx-stock-analysis/"
    },
    {
     "text": "RXRX Recursion Pharmaceuticals, Inc. NASDAQ $3.24 -4.99%",
     "url": "https://clearank.com/stock/rxrx-stock-analysis/"
    },
    {
     "text": "ABBV AbbVie Inc. NYSE $261.77 +1.81%",
     "url": "https://clearank.com/stock/abbvie-abbv/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare MDT",
   "links": [
    {
     "text": "BSX vs MDT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/bsx-vs-mdt/"
    },
    {
     "text": "SCHD vs VYM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/schd-vs-vym/"
    },
    {
     "text": "ANET vs CSCO Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/anet-vs-csco/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "MDT Insider Trading Analysis",
   "facts": {
    "Bought": "$462.8K",
    "Sold": "$9.6M",
    "Insiders": "22",
    "Avg Transaction": "$1.7M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in MDT",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Sep 10, 2019",
       "cells": [
        "HAKAMI HOOMAN C. Officer",
        "Sell",
        "82.9K",
        "$8.9M"
       ]
      },
      {
       "label": "Aug 31, 2021",
       "cells": [
        "LERMAN BRADLEY E General Counsel",
        "Sell",
        "50.8K",
        "$6.8M"
       ]
      },
      {
       "label": "Sep 30, 2021",
       "cells": [
        "LERMAN BRADLEY E General Counsel",
        "Sell",
        "49.1K",
        "$6.2M"
       ]
      },
      {
       "label": "Dec 24, 2019",
       "cells": [
        "KUNTZ RICHARD E Officer",
        "Sell",
        "50.9K",
        "$5.8M"
       ]
      },
      {
       "label": "Dec 2, 2019",
       "cells": [
        "WHITE ROBERT JOHN Officer",
        "Sell",
        "52.2K",
        "$5.8M"
       ]
      },
      {
       "label": "Nov 1, 2019",
       "cells": [
        "WHITE ROBERT JOHN Officer",
        "Sell",
        "52.2K",
        "$5.7M"
       ]
      },
      {
       "label": "Jun 12, 2019",
       "cells": [
        "HAKAMI HOOMAN C. Officer",
        "Sell",
        "52.7K",
        "$5.1M"
       ]
      },
      {
       "label": "Feb 19, 2026",
       "cells": [
        "KIIL HARRY SKIP Officer",
        "Sell",
        "52.5K",
        "$5.1M"
       ]
      },
      {
       "label": "Sep 24, 2018",
       "cells": [
        "MARTHA GEOFFREY S Officer",
        "Sell",
        "49.8K",
        "$4.9M"
       ]
      },
      {
       "label": "Aug 28, 2018",
       "cells": [
        "KUNTZ RICHARD E Officer",
        "Sell",
        "47.2K",
        "$4.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Medtronic&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Medtronic (MDT) stock a buy right now?",
   "answer": "Medtronic (MDT) is currently rated as a Buy, with a consensus score of 70 and a median analyst target price of $106.00, suggesting a 13.1% upside from its current price of $93.75. The stock is trading above key moving averages and has a history of meeting earnings expectations."
  },
  {
   "question": "What is Medtronic's (MDT) stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Medtronic's (MDT) stock price is projected to be $108.44 in 2030 under a base case scenario, with a downside projection of $59.17 and an upside projection of $198.73. These are statistical outcomes, not guarantees."
  },
  {
   "question": "What are the key technical levels for Medtronic (MDT)?",
   "answer": "Medtronic (MDT) is trading above its 50-day SMA of $88.10 and its 200-day SMA of $89.44, indicating a positive trend. The RSI is neutral at 57.12, suggesting no immediate overbought or oversold conditions."
  },
  {
   "question": "How does Medtronic's (MDT) valuation compare to its peers?",
   "answer": "Medtronic (MDT) trades at a P/E ratio of 22.40 and a price-to-sales ratio of 3.10, both of which are below the sector medians of 31.9 and 3.7, respectively, suggesting a potentially attractive valuation relative to the Healthcare sector."
  },
  {
   "question": "What is the recent earnings performance of Medtronic (MDT)?",
   "answer": "Medtronic (MDT) recently reported an EPS of $1.45 for the quarter to September 2026, exceeding estimates by 4.32%. The company has a consistent track record of meeting or beating earnings expectations."
  },
  {
   "question": "Are there any significant insider transactions for Medtronic (MDT)?",
   "answer": "Insider activity for Medtronic (MDT) indicates a moderate sell signal, with total sales of $9.6 million and purchases of $462.8K in recent filings. This suggests a net selling pressure from insiders."
  },
  {
   "question": "What is the outlook for Medtronic (MDT) over the next 12 months?",
   "answer": "The outlook for Medtronic (MDT) is positive, with a median analyst target price of $106.00, implying a 13.1% upside. The company is expected to continue its steady revenue growth and maintain its profitability, supported by a strong analyst consensus."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$281.50",
    "change": "-0.13%",
    "url": "https://clearank.com/stock/stryker-syk/"
   },
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$222.36",
    "change": "+6.80%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "BMY",
    "name": "Bristol-Myers Squibb Company NYSE",
    "price": "$63.73",
    "change": "-0.58%",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.87",
    "change": "-2.62%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   },
   {
    "ticker": "TEM",
    "name": "Tempus AI Inc NASDAQ",
    "price": "$68.85",
    "change": "+10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "RGNX",
    "name": "Regenxbio Inc. NASDAQ",
    "price": "$7.95",
    "change": "-8.57%",
    "url": "https://clearank.com/stock/rgnx-stock-analysis/"
   },
   {
    "ticker": "RXRX",
    "name": "Recursion Pharmaceuticals, Inc. NASDAQ",
    "price": "$3.24",
    "change": "-4.99%",
    "url": "https://clearank.com/stock/rxrx-stock-analysis/"
   },
   {
    "ticker": "ABBV",
    "name": "AbbVie Inc. NYSE",
    "price": "$261.77",
    "change": "+1.81%",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   }
  ],
  "comparisons": [
   {
    "ticker": "BSX vs MDT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/bsx-vs-mdt/"
   },
   {
    "ticker": "SCHD vs VYM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/schd-vs-vym/"
   },
   {
    "ticker": "ANET vs CSCO Comparison",
    "name": "",
    "url": "https://clearank.com/compare/anet-vs-csco/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc.",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   },
   {
    "ticker": "CRCL",
    "text": "↓ 11.41%",
    "url": "https://clearank.com/stock/circle-internet-group-crcl/"
   },
   {
    "ticker": "TEM",
    "text": "↑ 10.67%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "EW",
    "text": "Edwards Lifesciences Corporation",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "NEOG",
    "text": "Neogen Corporation",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "OFIX",
    "text": "Orthofix Medical",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "QDEL",
    "text": "QuidelOrtho Corporation",
    "url": "https://clearank.com/stock/quidelortho-qdel/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/medtronic-mdt.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/medtronic-mdt.png",
     "width": "1280",
     "height": "720",
     "caption": "Medtronic plc (MDT) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/medtronic-mdt/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/medtronic-mdt/",
        "name": "Medtronic plc (MDT) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/medtronic-mdt/#webpage",
     "url": "https://clearank.com/stock/medtronic-mdt/",
     "name": "Medtronic plc (MDT) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-03T09:22:47+00:00",
     "dateModified": "2026-09-15T22:26:22+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/medtronic-mdt.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/medtronic-mdt/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/medtronic-mdt/#richSnippet",
     "headline": "Medtronic plc (MDT) Stock Forecast & Price Target (2026)",
     "name": "Medtronic plc (MDT) Stock Forecast & Price Target (2026)",
     "description": "Medtronic (MDT) stock: Healthcare, Medical Devices. $119.9B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-03T09:22:47+00:00",
     "dateModified": "2026-09-15T22:26:22+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Medtronic",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "MDT"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring ",
      "tickerSymbol": "MDT",
      "sameAs": "https://www.medtronic.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/medtronic-mdt/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/medtronic-mdt.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/medtronic-mdt/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Medtronic (MDT) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Medtronic (MDT) is currently rated as a Buy, with a consensus score of 70 and a median analyst target price of $106.00, suggesting a 13.1% upside from its current price of $93.75. The stock is trading above key moving averages and has a history of meeting earnings expectations."
     }
    },
    {
     "@type": "Question",
     "name": "What is Medtronic's (MDT) stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Medtronic's (MDT) stock price is projected to be $108.44 in 2030 under a base case scenario, with a downside projection of $59.17 and an upside projection of $198.73. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical levels for Medtronic (MDT)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Medtronic (MDT) is trading above its 50-day SMA of $88.10 and its 200-day SMA of $89.44, indicating a positive trend. The RSI is neutral at 57.12, suggesting no immediate overbought or oversold conditions."
     }
    },
    {
     "@type": "Question",
     "name": "How does Medtronic's (MDT) valuation compare to its peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Medtronic (MDT) trades at a P/E ratio of 22.40 and a price-to-sales ratio of 3.10, both of which are below the sector medians of 31.9 and 3.7, respectively, suggesting a potentially attractive valuation relative to the Healthcare sector."
     }
    },
    {
     "@type": "Question",
     "name": "What is the recent earnings performance of Medtronic (MDT)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Medtronic (MDT) recently reported an EPS of $1.45 for the quarter to September 2026, exceeding estimates by 4.32%. The company has a consistent track record of meeting or beating earnings expectations."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any significant insider transactions for Medtronic (MDT)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insider activity for Medtronic (MDT) indicates a moderate sell signal, with total sales of $9.6 million and purchases of $462.8K across 62 transactions. This suggests a net selling pressure from insiders."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Medtronic (MDT) over the next 12 months?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The outlook for Medtronic (MDT) is positive, with a median analyst target price of $106.00, implying a 13.1% upside. The company is expected to continue its steady revenue growth and maintain its profitability, supported by a strong analyst consensus."
     }
    }
   ]
  }
 ]
}